Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Coherus Oncology, Inc. - Common Stock (NQ:CHRS)

1.565 -0.065 (-3.99%)
Streaming Delayed Price Updated: 11:34 AM EDT, May 15, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Coherus Oncology, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
News headline image
Coherus Management to Present at the 43rd Annual J.P. Morgan Healthcare Conference
From Coherus BioSciences, Inc.
Via GlobeNewswire
News headline image
Coherus to Present Final Phase 2 Casdozokitug Combination Data in Patients with Metastatic Hepatocellular Carcinoma at ASCO-GI 2025
From Coherus BioSciences, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Recap: Coherus BioSciences Q4 Earnings ↗
 
Via Benzinga
News headline image
Earnings Preview For Coherus BioSciences ↗
 
Via Benzinga
News headline image
Why Is Coherus BioSciences Stock Trading Higher On Tuesday? ↗
Coherus sells Udenyca franchise for up to $558.4 million, shifts focus to immuno-oncology R&D, and plans clinical trials in hepatocellular carcinoma and NSCLC. 
Via Benzinga
News headline image
Coherus Announces Agreement to Divest UDENYCA® Franchise for up to $558 million to Intas Pharmaceuticals Ltd.
From Coherus BioSciences, Inc.
Via GlobeNewswire
News headline image
Coherus Management to Participate in the 2024 Citi Global Healthcare Conference
From Coherus BioSciences, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
 
Via Benzinga
News headline image
Coherus BioSciences Reports Third Quarter 2024 Financial Results and Provides Business Update
From Coherus BioSciences, Inc.
Via GlobeNewswire
News headline image
Coherus to Report Third Quarter 2024 Financial Results on November 6, 2024
From Coherus BioSciences, Inc.
Via GlobeNewswire
News headline image
CHRS Stock Earnings: Coherus BioSciences Beats EPS, Beats Revenue for Q2 2024 ↗
CHRS stock results show that Coherus BioSciences beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
News headline image
Coherus BioSciences Reports Second Quarter 2024 Financial Results and Provides Business Update
From Coherus BioSciences, Inc.
Via GlobeNewswire
News headline image
Coherus to Report Second Quarter 2024 Financial Results on August 8, 2024
From Coherus BioSciences, Inc.
Via GlobeNewswire
News headline image
Week In Review: Fosun Pharma Plans $690 Million Deal To Privatize Henlius, Its Biologics Subsidiary ↗
Shanghai Henlius Biotech agreed to be a wholly owned subsidiary of Fosun in a $690 million deal that values the company at $1.7 billion. Meanwhile, Suzhou Ascentage Pharma filed to list in the US to... 
Via Talk Markets
News headline image
Coherus BioSciences Announces Divestiture of YUSIMRY (adalimumab-aqvh) in a $40 Million Upfront All Cash Transaction
– Transaction aligns with Coherus’ strategic focus on oncology – 
From Coherus BioSciences, Inc.
Via GlobeNewswire
News headline image
Coherus BioSciences Appoints Rita Karachun, CPA, CGMA to its Board of Directors
Former Global Controller of Merck & Co., Inc. Enhances Financial, Operational and Strategic Transformational Expertise 
From Coherus BioSciences, Inc.
Via GlobeNewswire
News headline image
Coherus Management to Present at the 2024 Jefferies Global Healthcare Conference
From Coherus BioSciences, Inc.
Via GlobeNewswire
News headline image
Coherus Presents Preliminary Results from Phase I Dose Escalation Study of its Anti-chemokine receptor 8 (CCR8) Antibody, CHS-114, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
From Coherus BioSciences, Inc.
Via GlobeNewswire
News headline image
Coherus Management to Present at the TD Cowen 5th Annual Oncology Innovation Virtual Summit: Insights for ASCO & EHA
From Coherus BioSciences, Inc.
Via GlobeNewswire
News headline image
CHRS Stock Earnings: Coherus BioSciences Misses EPS, Misses Revenue for Q1 2024 ↗
CHRS stock results show that Coherus BioSciences missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024. 
Via InvestorPlace
News headline image
Coherus BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update
From Coherus BioSciences, Inc.
Via GlobeNewswire
News headline image
Coherus Announces Full Repayment of Pharmakon Advisors $75 Million Term Loan
From Coherus BioSciences, Inc.
Via GlobeNewswire
News headline image
Coherus Announces Clinical Collaboration with the Cancer Research Institute for a Novel Combination Evaluating LOQTORZI® (toripalimab-tpzi) with ENB Therapeutics' ENB-003 for the Treatment of Ovarian Cancer
From Coherus BioSciences, Inc.
Via GlobeNewswire
News headline image
Coherus to Report First Quarter 2024 Financial Results on May 9, 2024
From Coherus BioSciences, Inc.
Via GlobeNewswire
News headline image
Coherus Announces Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
From Coherus BioSciences, Inc.
Via GlobeNewswire
News headline image
Coherus Presents Preclinical Data for CHS-1000, a Novel Anti-ILT4 Antibody, at the 2024 AACR Annual Meeting
From Coherus BioSciences, Inc.
Via GlobeNewswire
News headline image
Why Coherus Biosciences Stock Tumbled on Thursday ↗
The company fell well short of expectations for its fourth quarter. 
Via The Motley Fool
News headline image
Coherus BioSciences Reports Fourth Quarter, Full Year 2023 Financial Results and Provides Current Business Update
From Coherus BioSciences, Inc.
Via GlobeNewswire
News headline image
Earnings Scheduled For March 13, 2024 ↗
Companies Reporting Before The Bell • Sangamo Therapeutics (NASDAQ:SGMO) is likely to report quarterly loss at $0.26 per share on revenue of $8.10 million. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.